These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31247018)

  • 1. Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.
    Rehan M
    PLoS One; 2019; 14(6):e0219180. PubMed ID: 31247018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches.
    Mohd Rehan
    J Mol Graph Model; 2015 Nov; 62():226-234. PubMed ID: 26500112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
    Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
    Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
    Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
    Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of PI3K/mTOR Signal Pathway Inhibitor XL765 on Human Leukemic KG-1 Cells].
    Wu P; Chen SN; Wang Q; He C; Zhang R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):729-734. PubMed ID: 31204923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
    Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3Kγ Kinase Using Computational Methods.
    Rehan M; Mahmoud MM; Tabrez S; Hassan HMA; Ashraf GM
    Anticancer Res; 2020 Aug; 40(8):4547-4556. PubMed ID: 32727785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
    Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
    Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM
    Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis.
    Zhao H; Chen G; Liang H
    Onco Targets Ther; 2019; 12():5415-5424. PubMed ID: 31360067
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
    Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.
    Álvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2021 Feb; 211():113109. PubMed ID: 33360802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Anti-Cancer Drug Candidate OSI-027 and its Analog as Inhibitors of mTOR: Computational Insights Into the Inhibitory Mechanisms.
    Rehan M
    J Cell Biochem; 2017 Dec; 118(12):4558-4567. PubMed ID: 28475291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold.
    Takeda T; Wang Y; Bryant SH
    J Comput Aided Mol Des; 2016 Apr; 30(4):323-30. PubMed ID: 26956874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
    Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
    Zhang J; Lv X; Ma X; Hu Y
    Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.